14 completed, 8 unknown, 1 not yet recruiting, 1 terminated. 24 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Completed 14, Unknown 8, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 2, Unknown 2, Not yet recruiting 1 |
Follow Peripheral Neuropathy: new trials by email Literature Review of Peripheral Neuropathy trials Research Report on Peripheral Neuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy DLBS1033, Placebo Comparator: Placebo + Standard Therapy - Diabetic Polyneuropathy, Peripheral Nervous System Diseases | Phase 2 / Phase 3 | Not yet recruiting | Universitas Sebelas Maret | 34 | 2026-03-01 | 2026-03-16 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients Silymarin, Placebo - Breast Cancer, Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Tanta University | 56 | 2022-10-28 | 2022-10-26 |
| "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients" Pentoxifylline, Paclitaxel, Placebo - Breast Cancer Female, Peripheral Neuropathy | Phase 2 / Phase 3 | Completed | Ain Shams University | 66 | 2021-10-03 | 2024-01-23 |
| Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy Salsalate, PLACEBO - Type 1 Diabetes, Peripheral Neuropathy | Phase 2 / Phase 3 | Completed | University of Michigan | 61 | 2016-10-01 | 2025-05-16 |
| Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy FOLFOX regimen, HD6610 Granule, HD6610 Granule placebo - Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Jiangsu Province Hospital of Traditional Chinese Medicine | 64 | 2015-08-01 | 2015-12-02 |
| Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain Lidocaine, Placebo - Peripheral Neuropathy | Phase 3 | Completed | Mahidol University | 29 | 2014-08-01 | 2022-11-30 |
| The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy Glutamine - Peripheral Neuropathy | Phase 3 | Unknown | Ankara Education and Research Hospital | 80 | 2013-12-01 | 2013-12-31 |
| Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients EMG - Multiple Myeloma, Peripheral Neuropathy | Phase 3 | Unknown | Wolfson Medical Center | 30 | 2009-04-01 | 2009-03-31 |
| Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer duloxetine hydrochloride, placebo - Neurotoxicity, Pain | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 231 | 2008-04-01 | 2017-04-26 |
| Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients ketamine/amitriptyline NP-H cream, placebo - Neurotoxicity, Pain | Phase 3 | Completed | Gary Morrow | 462 | 2007-10-01 | 2015-11-09 |
| Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer glutamic acid, placebo - Kidney Cancer, Leukemia | Phase 3 | Completed | University of South Florida | 250 | 2007-05-01 | 2021-08-11 |
| A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain Sativex®, Placebo - Pain, Peripheral Neuropathy | Phase 3 | Completed | Jazz Pharmaceuticals | 19 | 2007-03-01 | 2023-05-03 |
| Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy pregabalin - Peripheral Neuropathy, HIV Infections | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 220 | 2006-02-01 | 2021-01-22 |
| Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy pregabalin, Placebo - HIV Infections, Peripheral Neuropathy | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 302 | 2005-10-01 | 2021-02-09 |
| A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain. Sativex® - Pain, Peripheral Neuropathy | Phase 3 | Completed | Jazz Pharmaceuticals | 380 | 2005-10-01 | 2023-05-03 |
| A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia Sativex, Placebo - Pain, Peripheral Neuropathy | Phase 3 | Completed | Jazz Pharmaceuticals | 246 | 2005-08-01 | 2023-05-03 |
Showing 20 of 24. Sign in to see all of them.
Peripheral Nervous System Diseases (24) · Pain (12) · Agnosia (4) · Chronic Pain (4) · Diabetes Mellitus (4) · Marijuana Abuse (4) · Neurotoxicity Syndromes (4) · Somatoform Disorders (4) · Breast Neoplasms (3) · Diabetic Neuropathies (3) · HIV Infections (2) · Neuralgia (2) · Pain, Postoperative (2) · Peripheral Nerve Injuries (2) · Burkitt Lymphoma (1)
Nervous System Diseases (24) · Neuromuscular Diseases (24) · Pathological Conditions, Signs and Symptoms (13) · Neurologic Manifestations (12) · Signs and Symptoms (12) · Chemically-Induced Disorders (9) · Neoplasms (7) · Immune System Diseases (5) · Mental Disorders (5) · Neoplasms by Site (5) · Endocrine System Diseases (4) · Glucose Metabolism Disorders (4) · Metabolic Diseases (4) · Neurobehavioral Manifestations (4) · Nutritional and Metabolic Diseases (4)
nabiximols (4) · Glutamine (2) · Pregabalin (2) · Amifostine (1) · DLBS 1033 (1) · Duloxetine Hydrochloride (1) · Folfox protocol (1) · Glutamic Acid (1) · Ketamine (1) · Lidocaine (1) · Paclitaxel (1) · Pentoxifylline (1) · Silymarin (1) · Standard of Care (1) · Sugars (1)
Apurano Pharmaceuticals GmbH (4) · Jazz Pharmaceuticals (4) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · Ain Shams University (1) · Alliance for Clinical Trials in Oncology (1) · Ankara Education and Research Hospital (1) · Gary Morrow (1) · Gynecologic Oncology Group (1) · Jiangsu Province Hospital of Traditional Chinese Medicine (1) · Mahidol University (1) · Mayo Clinic (1) · Tanta University (1) · Universitas Sebelas Maret (1) · University of Michigan (1) · University of South Florida (1)
United States (9) · Germany (4) · United Kingdom (4) · Egypt (2) · Puerto Rico (2) · China (1) · Indonesia (1) · Israel (1) · Thailand (1) · Turkey (Türkiye) (1)
Barbara Hoggart, MBBS, FRCA (2) · David R. Freyer, DO, MS (1) · Eliezer Rachmilewitz, MD (1) · Ellen L. Smith, PhD, ARNP, AOCN (1) · Eric Sandler, MD (1) · Huo JieGe, M.D. (1) · Krisandi Hartanto, MD (1) · Linda Vahdat, MD (1) · Matthew A Butters, MD (1) · Mick Serpell, MB ChB, FRCA (1) · Rodica Pop-Busui, MD, PhD (1) · Scott Bradfield, MD (1) · Steven C. Plaxe, MD (1) · Supriya Mohile, MD (1)
PMID 14745057, PMID 16235318, PMID 17997224, PMID 23549581, PMID 24420962, PMID 24531792, PMID 26603828, PMID 39727210, PMID 8857633, PMID 9415498
U10CA037420 (1), U10CA081920 (1)